Summary
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Pipeline Review, H1 2016’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post Menopausal Osteoporosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Post Menopausal Osteoporosis
- The report reviews pipeline therapeutics for Post Menopausal Osteoporosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post Menopausal Osteoporosis therapeutics and enlists all their major and minor projects
- The report assesses Post Menopausal Osteoporosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post Menopausal Osteoporosis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Amgen Inc.
BiologicsMD, Inc.
Clonz Biotech Private Limited
Eli Lilly and Company
Enteris BioPharma, Inc.
Ligand Pharmaceuticals, Inc.
Merck & Co., Inc.
Oncobiologics, Inc.
Paras Biopharmaceuticals Finland Oy
Radius Health, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Post Menopausal Osteoporosis Overview 7
Therapeutics Development 8
Pipeline Products for Post Menopausal Osteoporosis - Overview 8
Post Menopausal Osteoporosis - Therapeutics under Development by Companies 9
Post Menopausal Osteoporosis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Post Menopausal Osteoporosis - Products under Development by Companies 13
Post Menopausal Osteoporosis - Companies Involved in Therapeutics Development 14
Amgen Inc. 14
BiologicsMD, Inc. 15
Clonz Biotech Private Limited 16
Eli Lilly and Company 17
Enteris BioPharma, Inc. 18
Ligand Pharmaceuticals, Inc. 19
Merck & Co., Inc. 20
Oncobiologics, Inc. 21
Paras Biopharmaceuticals Finland Oy 22
Radius Health, Inc. 23
Post Menopausal Osteoporosis - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
abaloparatide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
blosozumab - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
BMD-1111 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
calcitonin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
denosumab - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
denosumab biosimilar - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
denosumab biosimilar - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Drugs for Postmenopausal Osteoporosis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
lasofoxifene tartrate - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
odanacatib - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
romosozumab - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
teriparatide biosimilar - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
teriparatide biosimilar - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Post Menopausal Osteoporosis - Recent Pipeline Updates 56
Post Menopausal Osteoporosis - Dormant Projects 74
Post Menopausal Osteoporosis - Discontinued Products 75
Post Menopausal Osteoporosis - Product Development Milestones 76
Featured News & Press Releases 76
Apr 01, 2016: Radius Presents Analysis Results on Fracture Risk Reduction in Phase 3 ACTIVE Trial for Investigational Drug Abaloparatide-SC at the ENDO 2016 Annual Meeting 76
Apr 01, 2016: Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide 76
Mar 31, 2016: ermonix Pharmaceuticals to Give Lasofoxifene Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Disease 77
Mar 30, 2016: Radius Health Submits New Drug Application to the U.S. Food and Drug Administration for Abaloparatide-SC for the Treatment of Postmenopausal Women with Osteoporosis 78
Feb 21, 2016: Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis 79
Jan 04, 2016: EMA started the evaluation of Richter’s marketing authorization application for biosimilar teriparatide 80
Nov 17, 2015: Radius Health Has Submitted a Marketing Authorization Application for the Investigational Drug Abaloparatide-SC for the Treatment of Postmenopausal Osteoporosis in Europe 80
Oct 19, 2015: Enteris BioPharma’s Formulation Technology Enables Oral Delivery of Tarsa Therapeutics’ TBRIA - the First Oral Calcitonin for the Treatment of Postmenopausal Osteoporosis 81
Oct 19, 2015: TARSA Therapeutics' NDA For TBRIA, The First Oral Calcitonin For The Treatment Of Postmenopausal Osteoporosis, Accepted For Filing 81
Oct 12, 2015: Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85
List of Tables
Number of Products under Development for Post Menopausal Osteoporosis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Post Menopausal Osteoporosis - Pipeline by Amgen Inc., H1 2016 14
Post Menopausal Osteoporosis - Pipeline by BiologicsMD, Inc., H1 2016 15
Post Menopausal Osteoporosis - Pipeline by Clonz Biotech Private Limited, H1 2016 16
Post Menopausal Osteoporosis - Pipeline by Eli Lilly and Company, H1 2016 17
Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma, Inc., H1 2016 18
Post Menopausal Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 19
Post Menopausal Osteoporosis - Pipeline by Merck & Co., Inc., H1 2016 20
Post Menopausal Osteoporosis - Pipeline by Oncobiologics, Inc., H1 2016 21
Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016 22
Post Menopausal Osteoporosis - Pipeline by Radius Health, Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Post Menopausal Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2016 56
Post Menopausal Osteoporosis - Dormant Projects, H1 2016 74
Post Menopausal Osteoporosis - Discontinued Products, H1 2016 75
List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Targets, H1 2016 25
Number of Products by Stage and Targets, H1 2016 25
Number of Products by Mechanism of Actions, H1 2016 27
Number of Products by Stage and Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
